Nyrada Inc - Annual Report 2022

ANNUAL REPORT FY22 53 14. Subsidiaries 2022 ownership interest 2021 ownership interest Nyrada Pty Ltd 100% 100% Norbio No.2 Pty Ltd 100% 100% Cardio Therapeutics Pty Ltd 100% 100% 15. Events after reporting period On 1 August 2022 the Company announced the appointment of Dr. Gisela Mautner as a Non-Executive Director to its Board and retirement of Peter Marks. No other matters or circumstances has arisen since 30 June 2022 that has significantly affected, or may significantly affect the Consolidated Entity's operations, the results of those operations, or the Consolidated Entity's state of affairs in future financial years. 16. Cash flow information Reconciliation of loss after income tax to net cash used in operating activities 2022 2021 $ $ Loss after income tax expense for the year (3,959,661) (3,539,253) Adjustments for: Depreciation & amortisation 4,734 1,811 Share-based payments 966,951 1,111,622 Change in operating assets and liabilities Decrease/(increase) in trade and other receivables 207,096 (281,976) Increase/(decrease) in trade and other payables (197,978) (98,620) Increase/(decrease) in employee benefits 55,170 33,568 (2,923,688) (2,772,848) Reconciliation of Cash Cash at the end of financial year as included in the statement of cash flows is reconciled to the related items in the statement of financial position as follows: 2022 2021 $ $ Cheque account 421,940 220,229 USD account 2,450,841 4,122,025 Saving bonus 7,943,258 9,408,489 10,816,039 13,750,743

RkJQdWJsaXNoZXIy MjE2NDg3